-
Mashup Score: 14Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF - 8 month(s) ago
Abstract Background Approximately 25% of patients admitted to hospitals for worsening heart failure (WHF) are readmitted within 30 days. Objectives The authors conducted a post hoc analysis of the …
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 2
Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.
Source: HCP LiveCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0U.S. FDA approves Lexicon Pharma's drug for heart failure - 10 month(s) ago
The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc’s drug for a broad treatment of heart failure, including in adult patients with type 2 diabetes, the company said on Friday.
Source: ReutersCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
AbstractAims. The SOLOIST‐WHF trial demonstrated efficacy of sotagliflozin in patients with type 2 diabetes mellitus (T2DM) and recent worsening heart failure (
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New Analyses of Sotagliflozin to be Presented at ACC23 - 1 year(s) ago
February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana. The following analyses of…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 10
Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
CHICAGO — The dual SGLT inhibitor sotagliflozin reduced 30- and 90-day rates of CV mortality and HF-related events when administered before hospital discharge after an episode of worsening HF, according to new data from the SOLOIST trial.Approximately 25% of patients are readmitted within 30 days of a hospital discharge for a worsening HF episode and nearly half of such patients are
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2SCORED: Sotagliflozin shows robust MACE benefit - 2 year(s) ago
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SCORED: Sotagliflozin shows robust MACE benefit - 2 year(s) ago
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Sotagliflozin Reduces MACE Risk in Diabetic, Kidney Disease Patients in SCORED Trial - 2 year(s) ago
Study author Deepak L. Bhatt, MD, MPH, discusses the unique SGLT-1 and SGLT-2 inhibition derived from sotagliflozin, and how impactful its benefit may be.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
Sotagliflozin reduces relative risk of hospital readmissions for #HeartFailure by 53% & composite of #CVdeath or #HF readmission by 52% within 30 days of discharge. https://t.co/lTklnAUhn0 #JACCHF #SOLOISTWHF #SGLT2i #Sotagliflozin #CardioTwitter #GDMT @DLBHATTMD https://t.co/EsLrS0zRmv